Sevelamer - Sanofi
Alternative Names: PB 94; Phosblock; Renagel; Sevelamer hydrochloride - Sanofi; TasermityLatest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Genzyme Corporation
- Developer Chugai Pharmaceutical; Kyowa Hakko Kirin; Kyowa Kirin; Sanofi
- Class Antihyperglycaemics; Chlorinated hydrocarbons; Epoxy compounds; Hyperphosphataemia therapies; Polyamines; Small molecules
- Mechanism of Action Chelating agents; Glucagon-like peptide-1 receptor antagonists; Phosphate binding protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hyperphosphataemia
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for clinical-Phase-Unknown development in Type-2-diabetes-mellitus(In the elderly, In adults) in Denmark (PO, Suspension)
- 27 Sep 2021 Efficacy data from SeveX clinical trial in Type 2 diabetes mellitus presented at 57th Annual Meeting of the European Association for the Study of Diabetes (EASD-2021)
- 01 Sep 2021 Sanofi completes SeveX clinical trial in Type 2 diabetes mellitus (In adults, In elderly) in Denmark (PO) (NCT03739268)